Propanc Biopharma

NASDAQ: PPCB ↗$1.37 USD~$5M (microcap, July 2026) MCAP

#Metastatic Colorectal Cancer #Pancreatic Cancer #Tumor Microenvironment Modulation #Proenzyme-Based Oncology #Anti-Metastatic Therapy

Propanc Biopharma is a clinical-stage biopharmaceutical company developing a pipeline of proenzyme-based oncology therapeutics designed to suppress tumor growth and metastasis by targeting and modulating the tumor microenvironment. Lead candidate PRP is being advanced in metastatic colorectal and pancreatic cancers. The company is pursuing an OPAL (Opposite-Pole) technology platform based on the proenzyme theory of cancer.

Company Info

Sector:Biopharmaceuticals / Oncology (Proenzyme Therapeutics)

Headquarters:Melbourne, Australia (US operations: Knightsdale, NC)

Founded:2007

Website:www.propanc.com/

Upcoming Milestones & Key Dates

Q3 2026

Corporate

Q2 2026 financial results and PRP clinical-program update

Clinical Development Pipeline

PRP

Target: Proenzyme-based anti-cancer therapy targeting the tumor microenvironment

Metastatic colorectal cancer and pancreatic cancer

Preclinical

Phase 1

Phase 2

Phase 3

Approved

James Nathanielsz

Co-Founder, President, Chief Executive Officer and Chief Scientific Officer

Careers & Job Openings

See all open roles

Multiple Departments

Melbourne, Australia / Knightsdale, NC

Apply Now →